Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 14Triple Negative Breast Neoplasms 12Lung Neoplasms 12Neoplasm Metastasis 11Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Endometrial Neoplasms 7Fallopian Tube Neoplasms 6Esophageal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Adenocarcinoma Of Esophagus 4Mouth Neoplasms 3Laryngeal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Inflammatory Breast Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Esophageal Squamous Cell Carcinoma 2Brenner Tumor 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2Adenocarcinoma 2

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × Taxes × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡